UBS Cuts Price Target on PG&E Corp. (PCG) to $64; Reiterates Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St futures rise as AI stocks rally, crude prices fall
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Crypto stocks rise premarket as Bitcoin hits over seven-month high
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- FortuneX and WT Realty announce $600M merger deal
Jefferies Cuts Price Target on PG&E Corp. (PCG) to $68 Following 3Q EPS Miss
November 8, 2016 7:17 AM ESTJefferies maintained a Buy rating on PG&E Corporation (NYSE: PCG), and cut the price target to $68.50 (from $70.00), following the company's 3Q earnings report. PCG reported EPS of $0.94, coming in below consensus estimates of $1.09. Management affirmed 2016 guidance of $3.65-$3.85.
Analyst Anthony Crowdell... More
PG&E Corp. (PCG) Misses Q3 EPS by 15c; Guides FY17 EPS
November 4, 2016 9:06 AM EDTPG&E Corp. (NYSE: PCG) reported Q3 EPS of $0.94, $0.15 worse than the analyst estimate of $1.09. Revenue for the quarter came in at $4.81 billion versus the consensus estimate of $5.01 billion.
GUIDANCE:
PG&E Corp. sees FY2017 EPS of $3.55-$3.75, versus the... More
Trading Radar for 11/4: Duke Energy (DUK), Genworth Financial (GNW), Shutterstock (SSTK), TDS (TDS) Report
November 3, 2016 2:07 PM EDTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EDT
Earnings:
AES Corp (NYSE: AES) - no Street consensus
ALLETE, Inc. (NYSE: ALE) - consensus EPS $0.96
Aratana Therapeutics (Nasdaq:... More

